Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.

Samuel Rosner Joshua E Reuss Marianna Zahurak Jiajia Zhang Zhen Zeng Janis M Taube Valsamo Anagnostou Kellie N Smit Joanne Riemer Peter B Illei Stephen R Broderick David R Jones Suzanne L Topalian Drew M Pardoll Julie R Brahmer Jamie E Chaft Patrick M Forde

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Five-year clinical outcomes for neoadjuvant nivolumab in resectable NSCLC compare favorably with historical outcomes. MPR and PD-L1 positivity trended toward improved RFS, though definitive conclusions are limited by cohort size.

Keyphrases

locally advanced
rectal cancer
squamous cell carcinoma
radiation therapy
small cell lung cancer
advanced non small cell lung cancer
lymph node
liver metastases
adipose tissue
weight loss
metabolic syndrome
epidermal growth factor receptor